SavedAdd your journal

Journals / Viral Hepatitis Journal / 2012 / Cilt: 18 - Sayı: 3

Sensorineural Hearing Loss Due to Pegylated Interferon Alfa/Ribavirin Therapy: A Case Report

Pegile Interferon Alfa/Ribavirin Tedavisine Bağlı Gelişen Sensorinöral Tipte İşitme Kaybı: Olgu Sunumu

TUĞBA SARI
Süda Tekin KORUK
Alaaddin ZİREK
Pages
123–126
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, the development of sensorineural hearing loss in patient may suggest autoimmunity as the cause of this side effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The effect of interferon alpha in chronic viral hepatitis and common side effects are well known, but hearing loss have been rarely reported.
📊
Key Findings & Data:A 66-year- old woman was administered peg- interferon alpha-2a (180 mcg, one times a week) and ribavirin(1200 mg daily) with the diagnosis of chronic hepatitis C.
💡
Conclusion & Impact:In conclusion, the development of sensorineural hearing loss in patient may suggest autoimmunity as the cause of this side effect.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The effect of interferon alpha in chronic viral hepatitis and common side effects are well known, but hearing loss have been rarely reported. A 66-year- old woman was administered peg- interferon alpha-2a (180 mcg, one times a week) and ribavirin(1200 mg daily) with the diagnosis of chronic hepatitis C. At the eighth month of the treatment hearing loss developed. The finding of audiometry was sensorineural hearing loss. Our diagnosis sensorineural type hearing loss thought to be a side effect of peg-interferon. In conclusion, the development of sensorineural hearing loss in patient may suggest autoimmunity as the cause of this side effect.

Özet

Kronik viral hepatitlerin tedavisinde etkili olan interferon alfanın sık görülen yan etkileri iyi bilinmektedir fakat işitme kaybı nadir bildirilmektedir. 66 yaşında bayan hastaya kronik hepatit C tanısı ile pegile interferon alfa-2a (haftada bir kez 180 mcg) ve ribavirin (1200 mg/gün) başlandı. Tedavinin sekizinci ayında, hastada işitme kaybı gelişti. Odiyometri ile işitme kaybının sensorinöral tipte olduğu tespit edildi. Hastaya pegile interferonun yan etkisi olabileceği düşünülen sensorinöral tipte işitme kaybı teşhisi konuldu. Sonuç olarak hastada gelişen sensorinöral tip işitme kaybı yan etkisinin, nedeninin otoimmuniteye bağlı olabileceği düşünüldü.

🔖

Cite This Article

SARI, T., KORUK, S. T., ZİREK, A. (2012). Sensorineural Hearing Loss Due to Pegylated Interferon Alfa/Ribavirin Therapy: A Case Report. Viral Hepatitis Journal, Cilt: 18 - Sayı: 3, 123–126. https://ajindex.com/articles/332797

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Dusheiko G. Side effects 44of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26 (Suppl 1): S112-S21
  2. Elloumi H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, et al. Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J Gastroenterol. 2007; 13: 5411-2
  3. Ogundipe O and Smith S. Bell’s palsy during interferon therapy for chronic hepatitis C infection in patients with hemorrhagic disorders. Hemophilia. 2000; 6: 110-12
  4. Calvet MC, Gresser I. Interferon enhances the excitability of cultured neurones. Nature. 1979; 278(5704): 558-60
  5. Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha- interferon: a possible autoimmune- microvascular pathogenesis. J Laryngol Otol. 1998; 112: 962-3
  6. Kanda Y, Shigeno K, Kinoshita N, Nakao K, Yano M, Matsuo H. Sudden hearing loss associated with interferon. Lancet. 1994; 343(8906): 1134-5
  7. Scultz RM, Papamat.JD, Chirgos MA. Interferon: an inducer of macrophage activation by polyanions. Science. 1997; 197: 674-6
  8. Tunca A, Erbayrak M, Aytac S, Turkay C. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol. 2004; 15: 97-9
  9. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996; 24: 38-47
  10. Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda- Steindl P, et al. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol. 2004; 99: 873-7
  11. Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment:outcome after resumption of therapy during hepatitis C treatment:outcome after resumption of therapy. World J Gastroenterol. 2005; 14: 5392-3
  12. Piekarska A, Jozefowicz-Korczynska M, Wojcik K, Berkan E. Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. Int J Audiol. 2007; 46: 345-50
  13. Görür K, Kandemir O, Unal M, Ozcan C. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx. 2003; 30(1): 41